June 2, 2018
Breast cancer - ASCO18

Top ASCO 2018 Abstracts To Watch Out For In Breast Cancer

Abstract 506: PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results. Conclusion: Trastuzumab’s known side effects include a risk for heart problems. The women who had […]
June 1, 2017

Journey through ASCO 2015 to 2017

In ASCO 2017, it will be great to see the new treatment options i.e. IOs and their combinations paving their way in other tumors. It would be informative to see how the disease landscape has evolved with the advent of IOs in the last one year. Equally, it would be […]
April 14, 2017

China – Drug Approval Reform

China’s Food and Drug Administration has started implementing key reforms that are likely to be a game changer for pharma companies eyeing the Chinese market.  The presentation below highlights the key reforms:     Key Takeaways: Leveling of Phase 1 playing field: Pharma companies can run a phase 1 trial […]
December 26, 2016

Exhibitors at ESMO

65 big/small/medium Pharmaceutical companies and 10 publishers took part in the ESMO. A white based theme was observed for all the booths in the ESMO Exhibition area. The booths attracted a lot of footfall and were packed right from day 1 of the conference.  Most of the companies of our […]
December 26, 2016

1L EGFRm+ NSCLC

AZ Shows Off osimertinib setting the groundwork for move into 1L EGFRm+ NSCLC AZ´s symposium presentations focused on promoting the value of 3rd Gen TKIs and liquid biopsies. AZ took the opportunity to emphasize that osimertinib is the only 3rd Gen TKI in the market highlighting the discontinuation of rociletinib […]
December 26, 2016

I/O highlights at ESMO

Merck carried off the prize in 1st Line NSCLC with KEYNOTE-021G and KEYNOTE-024 data Keytruda showed impressive results in 1L NSCLC both as a monotherapy and in combination with chemo. In the monotherapy study (KEYNOTE-024) focused on high PD-L1 expressors (TPS ≥50%), Keytruda gave superior results versus chemotherapy (mPFS: 10.3 […]